'Vaccine prince': the Indian billionaire set to make Covid jabs for the UK

Serum Institute boss Adar Poonawalla has rented a Mayfair mansion for £50,000 a week

The AstraZeneca vaccine has made Prof Sarah Gilbert – who led the Oxford team that created it – one of the UK’s most famous modern scientists and turned the Anglo-Swedish pharmaceutical company into a household name.

But almost half of all the AstraZeneca shots, destined for the arms of hundreds of millions of people around the world, are being produced by a 40-year-old Indian billionaire with a penchant for private jets and Picassos.

Adar Poonawalla, the self-proclaimed “prince of vaccines”, is chief executive of the Serum Institute of India (SII), the world’s largest vaccine producer, which even before coronavirus struck was making more than 1.5bn jabs a year for everything from polio and diphtheria to tetanus, BCG, hepatitis B and the MMR (measles, mumps and rubella) vaccinations.

Vaccines have made Poonawalla and his family extraordinarily wealthy. They are now the sixth richest family in India with an estimated $15bn (£11bn) fortune, according to the Times of India.

A woman walks past a painting welcoming the Covid-19 vaccination programme with a portrait of Adar Poonawalla
A woman walks past a painting welcoming the Covid-19 vaccination programme with a portrait of Adar Poonawalla. Photograph: Ashish Vaishnav/SOPA Images/Rex/Shutterstock

Among their portfolio of properties is Lincoln House, a Mumbai mansion which is the former US embassy to India. At $113m it was the most expensive Indian home ever sold when they bought it in 2015.

Poonawalla, who was educated at £30,000-a-year St Edmund’s School in Canterbury and the University of Westminster, this week signed a deal to rent a Mayfair mansion for a record £50,000 a week.

The property, which at 2,3oo sq metres (25,000 sq ft) is 24 times the size of the average English home, comes with an adjoining guest house and backs on to one of Mayfair’s “secret gardens”. He is renting it from Polish billionaire Dominika Kulczyk, who bought it for £57m last year.

Poonawalla, who is married with two children, travels by helicopter and private jet. He owns paintings by Picasso, Dalí, Rembrandt and Rubens, and has a collection of 35 rare luxury cars including several Ferraris, Bentleys and Rolls-Royces, as well as a Mercedes S350 converted into a replica Batmobile.

Adar Poonawalla’s replica Batmobile

His personal website admits his lifestyle looks flash. “It is easy to dismiss Adar Poonawalla as a rich brat … posing next to racehorses,” it says. But, it then adds, “the flamboyance is cultivated” and that he is actually “a serious young man who has been trained by a difficult boss – his father Cyrus Poonawala”.

Producing vaccines was not Poonawalla’s idea. His father, Cyrus, founded SII in 1966 as a sideline to his 81-hectare (200-acre) thoroughbred racehorse stables Poonawalla Stud. (Serum from purified horse blood was used in the production of early vaccines for diphtheria, tetanus, and scarlet fever.)

But it was Poonawalla who convinced his father to “go big” on vaccines after he watched a Bill Gates talk in 2015, in which the billionaire Microsoft co-founder-turned philanthropist warned that the world was not prepared for a new viral pandemic.

“I wanted to be prepared for a pandemic-level event ever since I heard Bill Gates in a Ted talk where he clearly said that we should be more worried and prepared for such situations,” Poonawalla told the Hindustan Times.

He doubled the firm’s production facilities and began producing more vaccines for developing countries on behalf of the World Health Organization and Global Alliance for Vaccines and Immunisation (Gavi), the vaccine charity supported by Gates and of which Poonawalla is a board member.

The “vaccine prince” title stuck when Poonawalla was appointed chief executive of SII in 2011, replacing his “vaccine king” father, who is now chairman of wider Poonawalla Group, which includes SII.

The Serum Institute of India campus in Pune
The Serum Institute of India campus in Pune, where it makes Covid-19 vaccine. Photograph: Punit Paranjpe/AFP/Getty Images

When coronavirus struck, Poonawalla had a decision to make: “Do absolutely nothing and watch how it unfolds, or take the risk and become a frontrunner.” He took the risk.

At the time the institute was working with Oxford University on developing a new malaria vaccine, and its scientists asked to collaborate on the Gilbert vaccine.

Last May, Poonawalla met the AstraZeneca chief executive, Pascal Soriot, on a video call, and negotiated a deal for SII to manufacture about 1bn doses over 12 months – almost half the overall total.

The same month a package arrived at SII’s vast campus in Pune, 150km south-east of Mumbai. Packed in dry ice was a vial containing the components needed to create the Oxford vaccine, cell substrate in which to grow it and detailed instructions. Not included were the results of any clinical trials or regulatory approvals that the vaccine was effective or even safe.

A worker fills Covid-19 vaccine phials at the Serum Institute of India factory in Pune
A worker fills Covid-19 vaccine phials at the Serum Institute of India factory in Pune. Photograph: Rafiq Maqbool/AP

Nevertheless, Poonawalla ordered three of his factories – which were at the time making “some very lucrative [other] vaccines” – to immediately switch production to the Oxford/AstraZeneca coronavirus vaccine AZD1222.

“Nobody wishes for a pandemic, but we were almost designed for one,” he told the Guardian earlier this year from his office inside a converted Airbus A320 jet, that he describes as “kind of similar to Air Force One”.

“We produce a 1.5bn vaccine doses each year. We never imagined the whole world being so dependent on us, but nobody else has our capacity to scale up,” he said. The decision to invest, he added, was easy because the firm is a private business “and not accountable to investors and bankers and shareholders”.

Instead, he says, “it was just a quick five-minute chat between myself and my father.” It was also, he admits, “a huge gamble – huge, huge, huge. People said I was crazy or stupid doing such a big bet at that time.”

Airport staff unload boxes of vaccine manufactured by the Serum Institute of India at Mumbai airport.
Airport staff unload boxes of vaccine manufactured by the Serum Institute of India at Mumbai airport. Photograph: Indranil Mukherjee/AFP/Getty Images

By the time the vaccine received its first regulatory approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in December 2020, SII had already made 40m doses. (The WHO approved it in February, but the US Food and Drugs Administration (FDA) has yet to grant its approval.)

The institute is now producing 80m doses a month, and is aiming for 100m doses a month soon, although a fire at one of its manufacturing facilities in January knocked it off target.

Dear countries & governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best.

— Adar Poonawalla (@adarpoonawalla) February 21, 2021

But SII’s huge production has thrown it and Poonawalla into the global political spotlight, as world leaders battle for doses and India – grappling with its own surge in Covid cases – wants the country’s production lines to supply it first.

Last month Poonawalla tweeted: “Dear countries & governments, as you await #COVISHIELD supplies, I humbly request you to please be patient, @SerumInstIndia has been directed to prioritise the huge needs of India ... We are trying our best.”

This week the Indian government introduced a de facto two- to three-month ban on vaccine exports, which will have repercussions in the UK, Europe and in the low- and middle-income countries signed up to the WHO’s Covax scheme.

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

The controls will delay 5m doses due to be shipped to the UK. The impending shortage means the UK vaccination programme has been set back by a month and that vaccinations will not be widely offered to under-50s until 1 May.

Back in India, Poonawalla is building yet another factory. This $400m facility, which is due to open in 2024, is designed to produce 1bn vaccine doses a year. It may be too late to help with the current coronavirus vaccine drive, but it is the next pandemic that is now on Poonawalla’s mind.

“Maybe not in my lifetime, but at least in my children’s lifetimes, there’s going to be another global pandemic,” he told Bloomberg. “And I’m willing to bet anything that pandemic will be far worse than this.”

Contributor

Rupert NeateWealth correspondent

The GuardianTramp

Related Content

Article image
Revealed: big shortfall in Covax Covid vaccine-sharing scheme
Only a fifth of Oxford/AstraZeneca doses expected by May delivered as export bans, hoarding and supply shortages bite

Michael Safi and Ashley Kirk

22, Apr, 2021 @9:35 AM

Article image
Oxford Covid-19 vaccine is still possible this year, says AstraZeneca chief
Pharmaceutical firm’s boss says 2020 deadline possible if regulators move fast

Julia Kollewe

10, Sep, 2020 @9:15 AM

Article image
From Pfizer to Moderna: who's making billions from Covid-19 vaccines?
The companies in line for the biggest windfalls – and the shareholders who have already made fortunes

Julia Kollewe

06, Mar, 2021 @11:55 AM

Article image
AstraZeneca CEO hits back at Covid vaccine supply criticism
Pascal Soriot says firm is doing its best to produce more and ‘should be proud of what we did in the world’

Julia Kollewe

30, Apr, 2021 @11:30 AM

Article image
Drug firms poised to make billions of dollars from Covid booster jabs
Sales of BioNTech, Moderna and Pfizer drugs could rival $6bn-a-year market for flu vaccines, say analysts

Julia Kollewe

13, Aug, 2021 @4:24 PM

Article image
AstraZeneca could supply potential coronavirus vaccine from September
Firm has capacity to make 1bn doses of Oxford University drug undergoing trials

Staff and agencies

21, May, 2020 @12:08 PM

Article image
Vaccines were not part of AstraZeneca’s grand strategy, so what’s the plan now?
Having built a big operation during the pandemic it could stick or twist but either way investors will soon want a decision

Nils Pratley

15, Jun, 2021 @6:40 PM

Article image
Thailand starts Covid vaccine drive using jabs made by king’s firm
Country aims to vaccinate 70% of people this year but experts express doubts amid supply concerns

Rebecca Ratcliffe in Bangkok

07, Jun, 2021 @3:14 PM

Article image
AstraZeneca partners with Oxford University to produce Covid-19 vaccine
Drugmaker will manufacture and distribute vaccine if human trials are successful

Joanna Partridge

30, Apr, 2020 @4:50 PM

Article image
Covid jabs for billions of humans will earn their makers billions of dollars
We look at the drug firms – led by Pfizer and Moderna – that are set to profit most in an unprecedented global vaccination drive

Julia Kollewe

19, Jun, 2021 @3:00 PM